InsidersTradesSigma
CytoDyn Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the CytoDyn Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, CytoDyn Inc. has recorded 53 reports. Market capitalisation: €471.7m. The latest transaction was reported on 14 February 2023 (Attribution). Among the most active insiders: Kelly Scott A.. All data is accessible without an account.
53
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 14 February 2023
Declarations53 total
434,782 sharesCommon StockSEC:0001104659-23-022094:0
16,927 shares0Common StockSEC:0001104659-22-123365:0
12,008 shares0Common StockSEC:0001104659-22-123366:0
15,234 shares0Common StockSEC:0001104659-22-119979:0
10,807 shares0Common StockSEC:0001104659-22-119981:0
13,671 shares0Common StockSEC:0001104659-22-119978:0
16,084 shares0Common StockSEC:0001104659-22-114098:0
12,714 shares0Common StockSEC:0001104659-22-114100:0
17,922 shares0Common StockSEC:0001104659-22-114101:0
9,824 shares0Common StockSEC:0001104659-22-109690:0
13,849 shares0Common StockSEC:0001104659-22-109687:0
12,428 shares0Common StockSEC:0001104659-22-109693:0
10,292 shares0Common StockSEC:0001104659-22-105981:0
13,020 shares0Common StockSEC:0001104659-22-105983:0
18,793 shares0Common StockSEC:0001104659-22-105980:0
646,552 shares0Common StockSEC:0001104659-22-102416:0
8,965 shares0Common StockSEC:0001104659-22-101254:0
9,457 shares0Common StockSEC:0001104659-22-101258:0
7,086 shares0Common StockSEC:0001104659-22-101256:0
10,516 shares0Common StockSEC:0001104659-22-097602:0
11,094 shares0Common StockSEC:0001104659-22-097603:0
8,313 shares0Common StockSEC:0001104659-22-097604:0
6,588 shares0Common StockSEC:0001104659-22-092175:0
5,208 shares0Common StockSEC:0001104659-22-092173:0
6,950 shares0Common StockSEC:0001104659-22-092174:0
25 of 53 declarations
About CytoDyn Inc.
Geographically, CytoDyn operates primarily from the United States and maintains its headquarters in Vancouver, Washington. The company’s development work is centered on U.S. clinical and regulatory pathways, with academic collaborations involving U.S. research institutions. Recent milestones matter for market perception: new oncology data were presented in 2026, an investor webcast was held on April 30, 2026, and the company publicly discussed ongoing phase 2 colorectal cancer work and planned phase 2 mTNBC activity. For investors in France, Belgium, and Switzerland, CytoDyn should be viewed as a speculative clinical-stage biotech with a single dominant scientific thesis, significant upside optionality if its CCR5/leronlimab program succeeds, and substantial execution risk if clinical or regulatory readouts disappoint.
